John W. Ryan

Q: What Schools Are Affiliated With John W. Ryan

John W. Ryan is affiliated with the following schools: University of California, Berkeley, Indiana University Bloomington, Indiana University, University of Alberta, University of Massachusetts Amherst, University of Wisconsin–Madison, Stanford University, University of Chicago, University of Utah

John W. Ryan's AcademicInfluence.com Rankings

John W. Ryan

Political Science

#1616

World Rank

#1916

Historical Rank

#800

USA Rank

political-science Degrees

Download Badge

Political Science

John W. Ryan's Degrees

PhD Political Science University of California, Berkeley
Masters Political Science University of California, Berkeley
Bachelors Political Science University of California, Berkeley

Why Is John W. Ryan Influential?

(Suggest an Edit or Addition)

According to Wikipedia, John William Ryan was an American academic administrator who most notably served as the President of Indiana University for sixteen years. Early life and career Ryan was born in Chicago, Illinois and earned a B.A. from the University of Utah in 1951, where he was a 1950 initiate of the Kappa Sigma Fraternity. He earned master's and Ph.D. degrees from Indiana University in 1958 and 1959, respectively. While in graduate school, Ryan served in two professional roles: first as a research analyst in the Kentucky Department of Revenue, then in establishing the graduate public administration program at Thammasat University. After graduating, he taught political science at the University of Wisconsin–Madison. In 1962, he became executive assistant to the president of the University of Massachusetts Amherst before moving to Arizona State University at Tempe to assume the vice presidency for academic affairs. He returned East to serve as the first chancellor of the University of Massachusetts Boston from 1965 to 1968.

(See a Problem?)

John W. Ryan's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Pulmonary arterial hypertension: pathogenesis and clinical management (2018) (484)
The Impact of COVID-19 on Medical Education (2020) (479)
Dynamin-Related Protein 1–Mediated Mitochondrial Mitotic Fission Permits Hyperproliferation of Vascular Smooth Muscle Cells and Offers a Novel Therapeutic Target in Pulmonary Hypertension (2012) (348)
The Right Ventricle in Pulmonary Arterial Hypertension: Disorders of Metabolism, Angiogenesis and Adrenergic Signaling in Right Ventricular Failure (2014) (347)
Dynamin‐related protein 1 (Drp1)‐mediated diastolic dysfunction in myocardial ischemia‐reperfusion injury: therapeutic benefits of Drp1 inhibition to reduce mitochondrial fission (2014) (273)
Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report (2019) (181)
Cardiovascular Effects of Exposure to Cigarette Smoke and Electronic Cigarettes: Clinical Perspectives From the Prevention of Cardiovascular Disease Section Leadership Council and Early Career Councils of the American College of Cardiology. (2015) (170)
PGC1α-mediated mitofusin-2 deficiency in female rats and humans with pulmonary arterial hypertension. (2013) (151)
Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension (2013) (143)
Kidney Transplantation and Gender Disparity (2005) (140)
Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part I Metabolic Plasticity and Mitochondrial Dynamics in the Pulmonary Circulation and Right Ventricle in Pulmonary Arterial Hypertension (2015) (135)
Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension (2013) (135)
Right ventricular adaptation and failure in pulmonary arterial hypertension. (2015) (133)
Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. (2011) (123)
FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate (2012) (119)
Lung ¹⁸F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. (2012) (118)
Mitochondrial dynamics in pulmonary arterial hypertension (2015) (118)
A Randomized Trial of Social Media From Circulation (2015) (111)
GRK2-Mediated Inhibition of Adrenergic and Dopaminergic Signaling in Right Ventricular Hypertrophy: Therapeutic Implications in Pulmonary Hypertension (2012) (109)
The role of redox signaling in epigenetics and cardiovascular disease. (2013) (101)
Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. (2019) (98)
Epigenetic mechanisms of pulmonary hypertension (2011) (89)
Role of Dynamin-Related Protein 1 (Drp1)-Mediated Mitochondrial Fission in Oxygen Sensing and Constriction of the Ductus Arteriosus (2013) (86)
Rodent models of pulmonary hypertension: harmonisation with the world health organisation’s categorisation of human PH (2011) (81)
Evidence of microvascular dysfunction in heart failure with preserved ejection fraction (2015) (80)
Endovascular therapy for acute ischaemic stroke: a systematic review and meta-analysis of randomized trials. (2015) (75)
Challenges facing early career academic cardiologists. (2014) (55)
Rodent models of group 1 pulmonary hypertension. (2013) (52)
Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic (2020) (49)
Randomized Controlled Trial of Social Media: Effect of Increased Intensity of the Intervention (2016) (49)
Impaired skeletal muscle vasodilation during exercise in heart failure with preserved ejection fraction. (2016) (46)
Evolving epidemiology of pulmonary arterial hypertension. (2012) (46)
The WHO classification of pulmonary hypertension: A case-based imaging compendium (2012) (45)
Minimizing the Risk of Bleeding with NOACs in the Elderly (2016) (39)
A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care (2020) (34)
The Right Ventricle under Pressure: Evaluating the Adaptive and Maladaptive Changes in the Right Ventricle in Pulmonary Arterial Hypertension using Echocardiography (2013 Grover Conference Series) (2015) (31)
The Heterogeneity of Clinical Practice Patterns among an International Cohort of Pulmonary Arterial Hypertension Experts (2014) (28)
Diagnosing and treating the failing right heart (2015) (27)
How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program (2016) (26)
Fall Risk Assessment Among Older Adults With Mild Alzheimer Disease (2011) (23)
The Prevalence of Health Promotion and Disease Prevention Education Within Physical Therapy Treatment Sessions (1998) (22)
Twitter as a New Core Competency for Cardiologists. (2018) (22)
Management of Pulmonary Arterial Hypertension (2020) (20)
Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension (2020) (20)
Therapy for Pulmonary Arterial Hypertension in Adults (2019) (19)
Pathophysiology, incidence, management, and consequences of cardiac arrhythmia in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (2019) (19)
A Review of the Role of Electronic Health Record in Genomic Research (2014) (18)
Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association (2016) (18)
Building the Case for Novel Clinical Trials in Pulmonary Arterial Hypertension (2015) (17)
The Emerging Role of Epigenetics in Pulmonary Arterial Hypertension: An Important Avenue for Clinical Trials (2015 Grover Conference Series) (2016) (16)
A Concerning Trend for Patients With Pulmonary Hypertension in the Era of Evidence-Based Medicine. (2019) (15)
Comparable benefit of β-blocker therapy in heart failure across regions of the world: meta-analysis of randomized clinical trials. (2014) (14)
A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with PAH or CTEPH and Impact on the Process of Care. (2020) (14)
Right‐to‐left ventricular end diastolic diameter ratio in severe sepsis and septic shock (2018) (14)
Current therapeutic approach in heart failure with preserved ejection fraction. (2014) (14)
Sex differences in response to pulmonary arterial hypertension therapy: is what's good for the goose, good for the gander? (2014) (13)
Cardiovascular Responses to Rhythmic Handgrip Exercise in Heart Failure with Preserved Ejection Fraction. (2020) (12)
H2 Receptor Antagonist Use and Mortality in Pulmonary Hypertension: Insight from the VA‐CART Program (2018) (11)
Amebic Liver Abscess in Childhood (1975) (11)
Impact of Acute Antioxidant Administration on Inflammation and Vascular Function in Heart Failure with Preserved Ejection Fraction. (2019) (11)
PGC1a-mediated Mitofusin-2 Deficiency in Female Rats and Humans with Pulmonary Arterial Hypertension (2013) (10)
Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report (2015) (10)
The Dyspnea Clinic. (2018) (10)
Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry. (2020) (9)
Pulmonary Arterial Hypertension in Primary Amyloidosis (2016) (9)
Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry (2020) (9)
Nitric Oxide Signaling in Heart Failure With Preserved Ejection Fraction (2017) (8)
Pulmonary Hypertension in Women. (2019) (8)
Endothelin-1, cardiac morphology, and heart failure: the MESA angiogenesis study. (2020) (7)
The Growing Burden of Pulmonary Hypertension in the Modern Era: A Zebra No More? (2018) (7)
Abstract 10963: Comparable Benefit of Beta-Blocker Therapy in Heart Failure across Regions of the World: Meta-Analysis of Randomized Clinical Trials (2013) (7)
Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease (2016) (7)
Pulmonary endarterectomy surgery--a technically demanding cure for WHO Group IV Pulmonary Hypertension: requirements for centres of excellence and availability in Canada. (2011) (7)
Chloroquine in pulmonary arterial hypertension: a new role for an old drug? (2013) (6)
Career Development of Young Physician-Scientists in the Cardiovascular Sciences: Perspective and Advice From the Early Career Committee of the Cardiopulmonary, Critical Care, and Resuscitation Council of the American Heart Association. (2018) (6)
Point of care ultrasound: the next evolution of medical education. (2020) (6)
CD47-Blocking Antibodies and Atherosclerosis (2016) (6)
Renal Function and Fluid and Electrolyte Balance (2001) (5)
Area handbook for Nicaragua (1970) (5)
Archer Angiogenesis and Adrenergic Signaling in Right Ventricular Failure The Right Ventricle in Pulmonary Arterial Hypertension : Disorders of Metabolism (2014) (5)
Stress-only imaging in patients with prior SPECT MPI: A simulation study (2012) (5)
Eisenmenger syndrome with unrepaired patent ductus arteriosus. (2015) (5)
Exploring the role of aldosterone in right ventricular function. (2014) (4)
An atypical presentation of cardiac tamponade and periorbital swelling in a patient with eosinophilic granulomatosis with polyangiitis: a case report (2017) (4)
Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry (2020) (4)
Novel techniques for advancing our understanding of pulmonary arterial hypertension (2019) (4)
A KCNE1 missense variant (V47I) causing exercise-induced long QT syndrome (Romano Ward). (2012) (4)
Evidence of impaired vasodilation during exercise in heart failure with preserved ejection fraction (1156.3) (2014) (4)
Nicaragua : a country study. (1982) (4)
Social Media Influence Does Not Reflect Scholarly or Clinical Activity in Real Life. (2020) (3)
Paracrine proliferative signaling by senescent cells in world health organization group 3 pulmonary hypertension: age corrupting youth? (2011) (3)
Patient Taking A Novel Oral Anticoagulant Presents With Major GI Bleeding. (2015) (3)
Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension. (2016) (3)
Area handbook for Mexico (1970) (3)
Response to letters regarding article, "A randomized trial of social media from Circulation". (2015) (3)
Treatment Differences in Pulmonary Arterial Hypertension Management (2016) (3)
Another Piece to the Puzzle: Linking the Cardiac Nervous System to Atrial Fibrillation in Pulmonary Arterial Hypertension. (2015) (3)
Sudden cardiac death due to large coronary aneurysm successfully treated with a covered stent and ChromaFlo guidance. (2011) (3)
Taking NO for an Answer: Exploring the Therapeutic Potential of Nitrite in HFpEF. (2016) (2)
RV/LV ratio in severe sepsis and septic shock: Response to Letter to the Editor. (2019) (2)
Pulmonary hypertension in heart failure: measurable, but how meaningful? (2015) (2)
Vericiguat in Heart Failure with Reduced Ejection Fraction. (2020) (2)
The complicated question of anticoagulation in pulmonary arterial hypertension: time to get some simple answers. (2014) (2)
Who's Who of Pulmonary Hypertension: Redefining Classification to Advance Precision Care. (2018) (2)
Machine Learning of the Cardiac Phenome and Skin Transcriptome to Categorize Heart Disease in Systemic Sclerosis (2017) (2)
The Approach to the Patient With Chronic Dyspnea of Unclear Etiology (2018) (2)
Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition. (2013) (2)
Evidence of an Exaggerated Muscle Metaboreflex Response in Heart Failure with Preserved Ejection Fraction (2017) (2)
Marriage : a medical and sacramental study (1955) (2)
Direct Assessment of Muscle Sympathetic Nerve Activity during Exercise in Heart Failure with Preserved Ejection Fraction: A Case Report. (2020) (2)
Quality of Life of Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Idiopathic Pulmonary Arterial Hypertension (IPAH): The Pulmonary Hypertension Association Registry (PHAR) (2020) (1)
Hemodynamics in Heart Failure (2020) (1)
Area Handbook for Mexico. First Edition. (1970) (1)
Feeding in Winter (1943) (1)
The Right Ventricle (2012) (1)
Empowering People Living with Heart Failure. (2020) (1)
Shortness of breath and cardiac conduction abnormality caused by infiltrative cardiomyopathy. (2015) (1)
Pulmonary hypertension in patients without pulmonary arterial hypertension (2016) (1)
Peripheral vascular function in heart failure patients with preserved ejection fraction (1156.4) (2014) (1)
Emergency department extracorporeal membrane oxygenation as a rescue therapy for ventricular tachycardia electrical storm: a case report (2020) (1)
Systematic Review/Meta-analysis Comparable Benefi to fb-Blocker Therapy in Heart Failure Across Regions of the World: Meta-analysis of Randomized Clinical Trials (2014) (1)
Cardiovascular Responses to Dynamic Handgrip Exercise in Patients with Heart Failure with Preserved Ejection Fraction (2018) (1)
Cardiovascular Responses During Graded Lower‐Body Negative Pressure in Heart Failure with Preserved Ejection Fraction (2020) (1)
Another Piece of the Puzzle (2013) (0)
Impact of Acute Antioxidant Administration on Inflammation and Vascular Function in Heart Failure with Preserved Ejection Fraction (2019) (0)
Correction to: Management of Pulmonary Arterial Hypertension (2020) (0)
Mitochondrial dynamics in pulmonary arterial hypertension (2015) (0)
PGClα-MEDIATED MITOFUSIN-2 DEFICIENCY IN PULMONARY ARTERIAL HYPERTENSION CAN BE REGRESSED BY PRO-FUSION AND ANTI-FISSION THERAPY (2013) (0)
Mitochondrial Reactive Oxygen Species and Redox State in Pulmonary Vascular O2 Sensing (2011) (0)
Abstract 328: An Outcomes Assessment of Vasodilator Therapy in Pulmonary Arterial Hypertension through Meta-analysis of 31 Randomized Controlled Trials (2014) (0)
Risk Prediction Models Are Associated with Patient Centered Outcomes in PAH: The Pulmonary Hypertension Association Registry (2020) (0)
Comparable Clinical Benefits with Beta-Blockers in Heart Failure Patients from North America and Europe: Evidence from a Meta-Analysis of Randomized Clinical Trials (2013) (0)
OXYGEN SPECIES INCREASED PRODUCTION OF REACTIVE VASOCONSTRICTION IS NOT MEDIATED BY COUNTERPOINT: HYPOXIC PULMONARY (2015) (0)
Abstract 16644: An Obligatory Role for Dynamin-Related Protein 1-Mediated Mitochondrial Fission in Oxygen-Sensing and Anatomical Closure of the Human Ductus Arteriosus (2012) (0)
Amyloidosis Cardiomyopathy Demonstrates Distinct Echocardiographic Patterns Compared to Patients with Heart Failure with Preserved Ejection Fraction (2016) (0)
Top advances in functional genomics and translational biology for 2012. (2013) (0)
Abstract 12688: Augmenting Mitofusin-2 in Females With Pulmonary Arterial Hypertension Increases Mitochondrial Fusion, Reduces Smooth Muscle Cell Hyperproliferation and Regresses Experimental Disease (2012) (0)
Editorial Exploring the Role of Aldosterone in Right Ventricular Function (2014) (0)
Predictors for the Development of Pulmonary Hypertension (PH) in Patients with Human Immunodeficiency Virus (HIV) Infection (0)
Competitive Fuels For The Future (1963) (0)
Abstract 16011: An Outcomes Assessment of Vasodilator Therapy in Pulmonary Arterial Hypertension Through Meta-Analysis of 31 Randomized Controlled Trials (2014) (0)
FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate (2012) (0)
Abstract 18282: Reducing Radiation in Patients with Prior SPECT Myocardial Perfusion Imaging: Is a Second Rest Study Really Necessary? (2010) (0)
Linking the Cardiac Nervous System to Atrial Fibrillation in Pulmonary Arterial Hypertension (0)
From bone morphogenic protein receptor II mutations to heritable pulmonary arterial hypertension-the long and winding road. (2017) (0)
Abstract 12188: Intensive Glycemic Control in Patients With Acute Coronary Syndrome: Evidence From a Meta-Analysis (2014) (0)
Improved Vascular Function Following 7 days of L‐Citrulline Administration in Heart Failure with Preserved Ejection Fraction (2020) (0)
Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension (2013) (0)
Feed for Milk-Eggs Pork (1942) (0)
Abstract 72: Inhibition of Dynamin Related Protein 1 Mediated Mitochondrial Fission During Cardiac Arrest Is Cardioprotective and Associated with Therapeutic Hypothermia (2012) (0)
Humpback whale song study data (2019) (0)
Inhibition Of G²³ Signaling Decreases Pulmonary Artery Pressure And Regresses Vascular Remodeling In Experimental Pulmonary Hypertension (2012) (0)
hypoxiaadaptive cardiac responses to chronic Gene expression profiling of sex differences in (2015) (0)
The Bach Family Looks at 1938 (1938) (0)
Recent Advances in Pulmonary Hypertension (2015) (0)
Response. (2019) (0)
A Change in Focus. (2019) (0)
Pathological Changes in Pulmonary Vasculature after Atrial Fibrillation Ablation (2016) (0)

This paper list is powered by the following services:

Other Resources About John W. Ryan

What Schools Are Affiliated With John W. Ryan?

John W. Ryan is affiliated with the following schools:

John W. Ryan's Academic­Influence.com Rankings